Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$2.03 USD
-0.01 (-0.49%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $2.02 -0.01 (-0.49%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
CLRB 2.03 -0.01(-0.49%)
Will CLRB be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CLRB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLRB
Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131
What's in Store for Cooper Companies (COO) in Q3 Earnings?
CLRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Broad Portfolio to Aid Patterson Companies' (PDCO) Q1 Earnings
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
Here's Why You Should Retain Accuray (ARAY) Stock for Now
Other News for CLRB
Warning: CLRB is at high risk of performing badly
Warning: CLRB is at high risk of performing badly
Cellectar Biosciences regains compliance with Nasdaq
Cellectar Biosciences regains compliance with Nasdaq
Cellectar Biosciences regains compliance with Nasdaq